ADJUVANT SYSTEMIC THERAPY FOR PRIMARY BREAST CANCER

This publication has 54 references indexed in Scilit:

• neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.
  Journal of Clinical Oncology, 1998
• Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approach
  Annals of Oncology, 1997
• High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.
  Journal of Clinical Oncology, 1997
• Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
  New England Journal of Medicine, 1995
• Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer
  New England Journal of Medicine, 1992
• Primary Chemotherapy To Avoid Mastectomy in Tumors With Diameters of Three Centimeters or More
  JNCI Journal of the National Cancer Institute, 1990
• Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer
  British Journal of Cancer, 1989
• Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer
  Breast Cancer Research and Treatment, 1985
• Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer a prospective randomized trial
  Cancer, 1984
• ON THE TREATMENT OF INOPERABLE CASES OF CARCINOMA OF THE MAMMA: SUGGESTIONS FOR A NEW METHOD OF TREATMENT, WITH ILLUSTRATIVE CASES.1
  The Lancet, 1896